Summary
Twenty six patients with pleural mesothelioma of UICC stage I–IV excluding M1 disease (46% of whom had stage I disease and 38% stage III disease) were treated intravenously with high dose MTX (3 g) and calcium folinate rescue three times at intervals of 2 weeks and three times at intervals of 3 weeks. Natural interferon (IFN)-α (3 MIU days 2–10) and recombinant IFN-γ 1b (50 μg m–2 on days 2, 6 and 10) were injected subcutaneously after each MTX dose. At the end of MTX treatment the IFNs were continued as maintenance therapy until disease progression. Seven partial responses were observed among 24 patients evaluable for response (response rate 29%, 95% confidence interval 13–51%). Median duration of response was 10 months (range 3–24 months). Median survival was 17 months and 1-year and 2-year survival rates 62% and 31% respectively. The toxicity of the chemo-immunotherapy was acceptable. Treatment was stopped in one patient who developed grade IV neurological toxicity. MTX dose reductions were rare (two patients with grade 1–2 renal toxicity). The combination of high dose MTX and IFN-α and IFN-γ is active against malignant pleural mesothelioma and well-tolerated. The survival rates are encouraging.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Ardizzoni, A., Pennucci, M. C., Castagneto, B., Mariani, G. L., Cinquegrana, A., Magri, D., Verna, A., Salvati, F. & Rosso, R. (1994). Recombinant interferon alpha-2b in the treatment of diffuse malignant pleural mesothelioma. Am J Clin Oncol (CCT) 17: 80–82.
Boutin, C., Nussbaum, E., Monnet, I., Bignon, J., Vanderschueren, R., Guerin, J-C, Menard, O., Mignot, P., Dabouis & Douillard, J-Y (1994). Intrapleural treatment with recombinant gamma-interferon in early stage malignant pleural mesothelioma. Cancer 74: 2460–2467.
Christmas, T. I., Manning, L. S., Garlepp, M. J., Musk, A. W. & Robinson, B. W. (1993). Effect of interferon-alpha 2a on malignant mesothelioma. J Interferon Res 13: 9–12.
Dimitrov, N. V., Egner, J., Balcueva, E. & Suhrland, L. G. (1982). High-dose methotrexate with citrovorum factor and vincristine in the treatment of malignant mesothelioma. Cancer 50: 1245–1247.
Dirix, L. Y., van Meerbeeck, J., Schrijvers, D., Corthouts, B., Prove, A., van Marck, E., Vermeire, P. & van Oosterom, A. T. (1994). A phase II trial of dose-escalated doxorubicin and ifosfamide/mesna in patients with malignant mesothelioma. Ann Oncol 5: 653–655.
Hand, A. M., Husgafvel-Pursiainen, K., Tammilehto, L., Mattson, K. & Linnainmaa, K. (1991). Malignant mesothelioma: the antiproliferative effect of cytokine combinations on three human mesotelioma cell lines. Cancer Lett 58: 205–210.
Hand, A. M., Pelin, K., Mattson, K. & Linnainmaa, K. (1995). Interferon (IFN)-α and IFN-γ in combination with methotrexate: in vitro sensitivity studies in four human mesothelioma cell lines. Anti-Cancer Drugs 6: 77–82.
Hunt, K. J., Longton, G., Williams, M. A. & Livingston, R. B. (1996). Treatment of malignant mesothelioma with methotrexate and vinblastine, with or without platinum chemotherapy. Chest 109: 1239–1242.
Ohnuma, T., Szrajer, L., Holland, J. F., Kurimoto, M. & Minowada, J. (1993). Effects of natural interferon alpha, natural tumor necrosis factor alpha and their combination on human mesothelioma xenografts in nude mice. Cancer Immunol Immunother 36: 31–36.
Ong, S. & Vogelzang, N. J. (1996). Chemotherapy in malignant pleural mesothelioma: a review. J Clin Oncol 14: 1007–1017.
Pass, H. W., Temeck, B. K., Kranda, K., Steinberg, S. M. & Pass, H. I. (1995). A phase II trial investigating primary immunochemotherapy for malignant pleural mesothelioma and the feasibility of adjuvant immunochemotherapy after maximal cytoreduction. Ann Surg Oncol 2: 214–220.
Rusch, V. (1995). A proposed new international TNM staging system for malignant pleural mesothelioma. Chest 108: 1122–1128.
Ryan, C. W., Herndon, J. & Vogelzang, N. J. (1998). A review of chemotherapy trials for malignant mesothelioma. Chest 113: 66S–73S.
Shin, D. M., Fossella, F. V., Umsawasdi, T., Murphy, W. K., Chasen, M. H., Walsh, G., Komaki, R., McMurtrey, M. J. & Hong, W. K. (1995). Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma. Cancer 76: 2230–2236.
Sklarin, N. T., Chaninian, A. P., Feuer, E. J., Lahman, L. A., Szrajer, L. & Holland, J. F. (1988). Augmentation of activity of cis-diamminedichloroplatinum(II) and mitomycin C by interferon in human malignant mesothelioma xenografts in nude mice. Cancer Res 48: 64–67.
Solheim, O. P., Säter, G., Finnanger, A. M. & Stenwig, A. E. (1992). High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study. Br J Cancer 65: 956–960.
Soulie, P., Ruffie, P., Trandafir, L., Monnet, I., Tardivon, A., Terrier, P., Cvitkovic, E., Le Chevalier, T. & Armand, J. P. (1996). Combined systemic chemoimmunotherapy in advanced diffuse malignant mesothelioma: report of phase I–II study of weekly cisplatin/interferon α-2a. J Clin Oncol 14: 878–885.
Stewart, D. J., Gertler, S. Z., Tomiak, A., Shamji, F., Goel, R. & Evans, W. K. (1994). High dose doxorubicin plus cisplatin in the treatment of unresectable mesotheliomas: report of four cases. Lung Cancer 11: 251–258.
Tansan, S., Emri, S., Selcuk, T., Koc, Y., Hesketh, P., Heeren, T., McCaffrey, R. P. & Baris, Y. I. (1994). Treatment of malignant pleural mesothelioma with cisplatin, mitomycin C and alpha interferon. Oncology 51: 348–3451.
UICC (1992). International Union against Cancer: TNM Classification of Malignant Tumours. Springer Verlag: Berlin
Upham, J. W., Musk, A. W., van Hazel, G., Byrne, M. & Robinson, B. W. (1993). Interferon alpha and doxorubicin in malignant mesothelioma: a phase II study. Aust NZ J Med 23: 683–687.
Von Hoff, D. D., Metch, B., Lucas, J. G., Balcerzak, S. P., Grunberg, S. M. & Rivkin, S. E. (1990). Phase II evaluation of recombinant interferon-beta (IFN-β ser) in patients with diffuse mesothelioma: a Southwest Oncology Group study. J Interferon Res 10: 531–534.
Zeng, L., Buard, A., Monnet, I., Boutin, C., Fleury, J., Saint-Etienne, L., Brochard, P., Bignon, J. & Jaurand, M. C. (1993). In vitro effects of recombinant human interferon gamma on human mesothelioma cell lines. Int J Cancer 55: 515–520.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Halme, M., Knuuttila, A., Vehmas, T. et al. High-dose methotrexate in combination with interferons in the treatment of malignant pleural mesothelioma. Br J Cancer 80, 1781–1785 (1999). https://doi.org/10.1038/sj.bjc.6690597
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.bjc.6690597
Keywords
This article is cited by
-
Current therapies for malignant pleural mesothelioma
Environmental Health and Preventive Medicine (2008)
-
Successful Treatment With Novel Triple Drug Combination Consisting of Interferon-γ, Interferon Alfacon-1, and Ribavirin in a Nonresponder HCV Patient to Pegylated Interferon Therapy
Digestive Diseases and Sciences (2006)
-
Current therapy for malignant mesothelioma
Current Oncology Reports (2002)
